Navigation Links
Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
Date:5/16/2008

-- 16,667

Total Current Liabilities 678,144 503,284

Convertible note, net of discount 819,525 --

Grant payable 99,728 99,728

Other liability 24,595 29,196

TOTAL LIABILITIES 1,621,992 632,208

STOCKHOLDERS' EQUITY:

Preferred stock, $0.01 par value; authorized

5,000,000 shares,

no shares issued -- --

Common stock, $0.01 par value; authorized

100,000,000 shares, 177,283 174,737

issued and outstanding 17,728,314 and

17,473,694, respectively

Capital in excess of par 35,925,622 28,136,342

Deficit accumulated during the development

stage (29,342,424) (25,621,540)

TOTAL STOCKHOLDERS' EQUITY 6,760,481 2,689,539

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $8,382,473 $3,321,747


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
2. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
5. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
6. Sturgeon and Caviar From Aquaculture: United Food Technologies AG Hands Over Turnkey Plant
7. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
8. Veran Medical Technologies Secures $4.75M in First Institutional Funding
9. Neurobiological Technologies Reports Third Quarter Financial Results
10. InSet Technologies Appoints Jon Tremmel to its Board of Directors
11. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The California Healthcare ... organization representing leading California academic institutions, biotechnology, medical ... US today released a report revealing that ... growth. The trend shows a 4 percent increase ... Biomedical Industry Report indicates that, while biopharmaceutical ...
(Date:11/21/2014)... November 21, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... ferrocyanide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... nine month periods ended September 30, 2014.  Biorem,s complete 2014 third ... www.sedar.com ). Financial Summary:Three-months ended September 30, ... per share data) , 2014 , 2013 ... 2,282 , 5,281 , 6,715 , ...
(Date:11/18/2014)... November 17, 2014 Athena Signature Series: Turning ... Dr. Beverly Emerson, a professor in the Regulatory Biology Laboratory ... most recent discovery points to an “off switch” for drug ... and how her local research is making a global impact ... findings and then join host Cheryl K. Goodman, CEO of ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... Universite de Montreal and Validapro Biosciences Inc. have signed an ... standards of the biotherapeutic manufacturing unit located at the Faculty ... veterinary clinical use. , ... Laval, ...
... 19 , - Completed ... Opsona Therapeutics, a biotechnology company focused ... diseases, today,announced that Roche Venture Fund and Enterprise Ireland ... financing announced in February,this year, bringing the total round ...
... for Mometasone Furoate/Formoterol Combination for Asthma and ... (NYSE: SGP ) today announced ... for the development and commercialization of fixed-dose ... and chronic obstructive pulmonary disease (COPD). ...
Cached Biology Technology:Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing 2Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 2Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 4Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 5Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 6Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 7Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 8
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... 11, 2011, Shenzhen, China BGI (previously known as the ... announced today that it was among the research organizations comprising ... sequence and analysis of the tuber crop potato, published as ... This study marks an important milestone in ...
... present in primitive fish millions of years before their ... Genetic switches control the timing and location of ... DNA is placed into mouse embryos, the segment can ... University of Chicago researchers report in Proceedings of ...
... researchers at The Wistar Institute shows how our cells create ... DNA. Many genes are associated with multiple gene promoters, the ... a given gene, for example, can be made with the ... journal Genome Research, available online now, show how genes are ...
Cached Biology News:BGI contributes whole genome sequencing and bioinformatics expertise to potato genome research 2BGI contributes whole genome sequencing and bioinformatics expertise to potato genome research 3Genetic switch for limbs and digits found in ancient fish 2Genetic switch for limbs and digits found in ancient fish 3Multiple 'siblings' from every gene: Alternate gene reading leads to alternate gene products 2Multiple 'siblings' from every gene: Alternate gene reading leads to alternate gene products 3
Request Info...
...
...
... agent. Inhibits several important steps of angiogenesis including ... cells. Also reduces intracellular reactive oxygen species (ROS) ... endothelial cells. Formula: ... MolWeight: 360.31484 ...
Biology Products: